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Kathryn E. McDougal1, M. Daniele Fallin2, David R. Moller3, Zhimin Song3, David J. Cutler4, Lori L. Steiner5,
Garry R. Cutting1,3,6 and the ACCESS Research Group
Sarcoidosis is a multi-system inflammatory disease with organ involvement that varies by race and sex. Family
studies indicate that genes play a role in the etiology and extent of organ involvement in sarcoidosis. In this
study, we evaluated whether 25 variants distributed in 19 genes with a known role in inflammation were
associated with erythema nodosum status in 659 sarcoidosis patients and 658 controls from A Case–Control
Etiologic Study of Sarcoidosis (ACCESS). We found no association with affectation status; however, a variant in
the promoter of tumor necrosis factor (TNF) at position 308 was found to be associated with erythema
nodosum in Caucasian sarcoidosis patients (study-wide P¼ 0.027). When separated by sex, a variant in intron 1
of lymphotoxin-a (LTA), a gene adjacent to TNF, was associated with erythema nodosum in female Caucasian
sarcoidosis patients (study-wide P¼ 0.027). These DNA variants frequently occur together in Caucasians, and
each variant has individually been associated with erythema nodosum in sarcoidosis patients. These results
confirm that variation in the LTA/TNF gene cluster modifies a major skin manifestation of sarcoidosis and may
explain the higher rate of erythema nodosum in females with sarcoidosis.
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INTRODUCTION
Sarcoidosis is a multi-systemic inflammatory disorder char-
acterized by noncaseating epithelial cell granulomas. Sarcoi-
dosis has a variable age of onset, usually 20–40 years.
Inflammation is most commonly found in lungs and lymph
nodes. Sarcoidosis occurs 10 times more frequently in African
Americans than in Caucasians (James, 1992). However, the
familial relative risk estimate for siblings and parents is
considerably lower in African Americans (3.1) compared to
Caucasians (16.6) (Rybicki et al., 2001a). Familial clustering
suggests that shared genetic and/or environmental compo-
nents, especially in Caucasians, contribute to sarcoidosis
(Rybicki et al., 2001b). Indeed, the major histocompatibility
locus on chromosome 6 has been implicated as an etiologic
factor in this disorder (Schurmann et al., 2000). In addition,
genome-wide linkage and fine mapping demonstrated that
butyrophilin-like 2, a member of the immunoglobin super-
family in the major histocompatibility region, was associated
with sarcoidosis (Valentonyte et al., 2005). Recent work
suggests butyrophilin-like 2 regulates T-cell activation by
binding to a receptor expressed on activated T-cells and
inhibiting T-cell proliferation (Nguyen et al., 2006).
Erythema nodosum (EN) is a major skin manifestation of
sarcoidosis. It is characterized by hard, painful nodules
occurring in 3–44% of patients and occurs more frequently in
women and, in some studies, Caucasians (Siltzbach et al.,
1974; Baughman et al., 2001; Grunewald and Eklund, 2007;
1999). Lo¨fgren’s syndrome, originally defined as sarcoidosis
with presence of EN and bilateral hilar lymphadenopathy
(Lofgren and Lundback, 1952a), has been associated with
single nucleotide polymorphisms (SNPs) in the HLA-DRB1/
LTA/TNF locus (Seitzer et al., 1997; Swider et al., 1999;
Labunski et al., 2001; Mrazek et al., 2005; Grunewald and
Eklund, 2007). However, the studies have not been convin-
cingly replicated. Some were limited to small groups of
patients and some did not distinguish between variants
analyzed as causal for sarcoidosis and variants modifying
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sarcoidosis phenotype. In addition, diversity of study design
and selection of controls add to the challenge of evaluating
these studies.
To examine the association between the LTA/TNF locus
and EN, we analyzed sarcoidosis patients and non-disease
controls recruited by A Case–Control Etiologic Study of
Sarcoidosis (ACCESS) on the basis of sarcoidosis affectation
status alone. SNPs in 19 genes involved in inflammatory
processes were genotyped and the significance for associa-
tion was derived at a study-wide level. Finally, patients were
analyzed in groups to determine if SNP variants accounted
for higher rates of EN in women and in Caucasians.
RESULTS
Lack of association between candidate SNPs and sarcoidosis
disease status
Twenty-five SNPs in 19 genes were typed in 659 sarcoidosis
patients and 658 controls recruited by ACCESS (Table 1). The
genotype distribution of 23 SNPs met the Hardy–Weinberg
Equilibrium (HWE) predictions in African Americans and
Caucasians. SNP rs1799987 met HWE predictions in African
Americans only and SNP rs333 met HWE predictions in
Caucasians only. Owing to racial differences in allele
frequencies, Caucasian patients were analyzed separately
(24 tests) from African-American patients (24 tests). No
SNPs reached significance in the Caucasian or the African-
American group, even when separated by sex. Study-wide
P-values and Q-values for all analyses are available in Tables
S1-S3.
Association between LTA/TNF loci and EN in sarcoidosis
patients
EN phenotype data were available for 362 Caucasian
sarcoidosis patients (100% of Caucasian cases) and 294
African-American patients (98.9% of African-American
cases). In these populations, 8.1% of Caucasian sarcoidosis
patients had EN (5.5% of male patients; 10% of female
patients). In addition, 9.5% of ACCESS African-American
sarcoidosis patients were affected with EN (2.6% of male
patients; 12.2% of female patients). The higher prevalence of
EN in female patients in ACCESS has been reported by others,
but the similar prevalence by race contrasts with other studies
(Baughman et al., 2001). As no SNPs were significant factors
in previous analysis of sarcoidosis disease status, no correc-
tions for potential confounding were needed. When both
sexes were analyzed together, genotypes at tumor necrosis
factor (TNF) SNP 308 showed an association with EN in
Caucasian patients, with an uncorrected P-value of 0.002 and
study-wide P-value of 0.027 (Table 2; data for all SNPs in
Tables S4 and S6). Similarly, the Q-value derived from the
false discovery rate (FDR) for the association with the
TNF-308 genotype is 0.048, indicating that if a P-value of
0.002 was set as a study-wide threshold, less than 5% of SNPs
reaching that level would be expected to be false positives
(Table 2). Odds ratio analysis revealed that Caucasian
sarcoidosis patients with the TNF-308 AA genotype had an
8-fold higher risk of developing EN compared to patients with
the GG genotype (homozygous odds ratio 8.182 (2.449,
27.339); Table 2).
When all SNPs were tested for association in patients with
EN according to sex, the TNF-308 genotype showed an
association with EN in Caucasian women (P¼ 0.002). This
association was just below the threshold for study-wide
significance using the permutation method. The Q-value
derived by FDR was 0.024, indicating a low probability that
the observed association was a false positive (Table 3). In
addition, the homozygous odds ratio for TNF-308 was 10.667
(2.495, 45.603), indicating an over 10-fold higher risk of EN
in females with the AA genotype compared to the GG
genotype. This is consistent with the homozygous odds ratio
of 8.182 in Caucasians as a whole.
Interestingly, Caucasian women with EN also showed a
strong association with genotypes at a SNP in lymphotoxin-a
(LTA), a gene immediately adjacent to TNF (study-wide
P¼0.027; Qo0.001; Table 3). Female patients with the
LTA GG genotype had an 11-fold higher risk compared to
Table 1. List of analyzed SNPs from inflammatory
genes
Gene SNP RS number
Complement component 3 AA102 G/R 2230199
Complement component 5 AA802 I/V 17611
Chemokine, CC motif receptor 2 AA62 I/V 1799864
Chemokine, CC motif receptor 5 wt/del 32 3331
Chemokine, CC motif receptor 5 (2454) A/G 17999872
Monocyte differentiation Antigen CD 14 (260) C/T 2569190
Colony-stimulating factor 2 AA117 I/T 25882
Cytotoxic T lymphocyte-associated 4 (318) C/T 5742909
Cytotoxic T lymphocyte-associated 4 AA17 A/T 231775
Intracellular adhesion molecule 1 AA56 K/M 5491
Intracellular adhesion molecule 1 AA241 G/R 1799969
Interleukin 1-alpha (889) C/T 1800587
Interleukin 6 (572) C/G 1800796
Interleukin 6 (174) C/G 1800795
Interleukin 10 (571) A/C 1800872
Interleukin 13 (int3) C/T 1295686
Lymphotoxin-alpha (int1) A/G 909253
Nitric oxide synthase 2A AA346D C/T 1137933
Selectin E AA149 R/S 5361
Tumor necrosis factor (308) A/G 1800629
Tumor necrosis factor (238) A/G 361525
Uteroglobin (+38) A/G 3741240
Vascular cell adhesion molecule 1 (1592) C/T 1041163
Vitamin D receptor AA1 M/T 2228570
Vitamin D receptor (int8) A/G 1544410
1Deviated from Hardy–Weinberg equilibrium in African-American control
and dropped from African-American analyses.
2Deviated from Hardy–Weinberg equilibrium in Caucasian controls and
dropped from Caucasian analyses.
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female patients with the AA genotype (homozygous odds
ratio 11.333 (3.182, 40.370); Table 3). Although no
genotypes achieved study-wide significance in African-
Americans (Table S4 and S5), there was a trend toward an
association between EN and LTA genotypes in African-
American women (Table 3). The Q-value for an association
between LTA genotypes and EN in African-American women
was 0.114, indicating a relatively low (11.4%) chance that
the observed association was a false positive if P¼0.047 was
defined as the threshold for a significant P-value (Table 3).
Haplotype analysis using the Exhaustive Allelic Case–-
Control method (Lin et al., 2004) indicated that risk alleles for
EN are frequently found together (that is, high linkage
disequilibrium) at the LTA/TNF locus. Upon investigation of
this region using Caucasian data publicly available from
HapMap (http://www.hapmap.org), the D’ measure of
linkage disequilibrium was shown to be 1.0, indicating an
extremely high degree of correlation between the two SNPs.
These SNPs are present in the same haplotype block and the
TNF-308 A allele is found only with the LTA G allele (Barrett
et al., 2005).
DISCUSSION
Large, well-characterized patient collections such as
ACCESS provide an excellent resource to evaluate the
association between candidate genes and disease manifesta-
tions. Several prior studies implicated genetic variation at the
LTA/TNF locus as a risk factor for development of EN in
Caucasian sarcoidosis patients (Seitzer et al., 1997; Swider
et al., 1999; Labunski et al., 2001; Mrazek et al., 2005;
Grunewald and Eklund, 2007). However, when attempting to
evaluate the genetic factors for a modifying role, it is
important to differentiate whether the genetic variants
contribute to affectation status (for example, causing
Table 2. Distribution of TNF 308 (rs1800629) genotypes in sarcoidosis patients with and without erythema
nodosum (EN)
Caucasian African American
Without EN With EN Without EN With EN
AA 12 (3.59%) 5 (18.52%) 1 (0.38%) 0 (0.00%)
AG 106 (31.74%) 11 (40.74%) 65 (24.62%) 6 (24.00%)
GG 216 (64.67%) 11 (40.74%) 198 (75.00%) 19 (76.00%)
Study-wide P-value1 0.027 1
Q-value2 0.048 0.531
Heterozygous odds ratio 2.038 (0.856, 4.852)3 0.962 (0.368, 2.511)
Homozygous odds ratio 8.182 (2.449, 27.339) NA4
1P-value corrected for multiple tests using Monte Carlo permutation.
2Estimate of the False Discovery Rate of the uncorrected P-value.
395% Wald confidence limits.
4Owing to small numbers.
Table 3. Distribution of TNF 308 (rs1800629) and LTA (rs909253) genotypes in female sarcoidosis patients with
and without erythema nodosum (EN)
TNF 308 LTA
Caucasian African American Caucasian African American
Without EN With EN Without EN With EN Without EN With EN Without EN With EN
AA 6 (3.17%) 4 (21.05%) 1 (0.53%) 0 (0%) 85 (44.97%) 5 (26.32%) 39 (20.74%) 3 (13.04%)
AG 55 (29.10%) 7 (36.84%) 46 (24.47%) 6 (26.09%) 92 (48.68%) 6 (31.58%) 104 (55.32%) 10 (43.48%)
GG 128 (67.72%) 8 (42.11%) 141 (75.00%) 17 (73.91%) 12 (6.35%) 8 (42.11%) 45 (23.94%) 10 (43.48%)
Study-wide P-value1 0.111 1 0.027 0.753
Q-value2 0.024 0.26 o0.001 0.114
Heterozygous Odds Ratio 2.036 (0.704, 5.892)3 1.082 (0.403, 2.907) 1.109 (0.326, 3.766) 1.250 (0.327, 4.782)
Homozygous Odds Ratio 10.667 (2.495, 45.603) NA4 11.333 (3.182, 40.370) 2.889 (0.742, 11.251)
1P-value corrected for multiple tests using Monte Carlo permutations.
2Estimate of the False Discovery Rate of the uncorrected P-value.
395% Wald confidence limits.
4Owing to small numbers.
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sarcoidosis) or whether they only associate with disease
complication (for example, EN). Thus, we first evaluated
whether any SNPs were associated with sarcoidosis disease
status in Caucasians (362 cases/364 controls) using an
unconditional logistic regression adjusted for each matching
factor. As none of the SNPs were associated with affectation
status, we assessed whether Caucasian sarcoidosis patients
with and without EN (27 with EN/ 334 without) were
associated with any of 24 variants in inflammatory genes. By
structuring the second phase of analysis in this manner, we
evaluated candidate variants only for a role in the presence or
absence of EN within sarcoidosis. The study design had two
additional strengths. First, analysis of patients recruited on the
basis of sarcoidosis rather than EN minimized ascertainment
bias. Second, typing of all patients for 24 variants in 19
biologically implicated candidate genes and use of a study-
wide threshold for significance provided a stringent test for
association.
Lo¨fgren’s syndrome, defined as sarcoidosis with the
presence of EN and bilateral hilar lymphadenopathy (Lofgren
and Lundback, 1952a, b), has been associated with SNPs in
the HLA-DRB1/LTA/TNF locus in Caucasians and in patients
of unspecified race (Seitzer et al., 1997; Swider et al., 1999;
Labunski et al., 2001; Mrazek et al., 2005; Grunewald and
Eklund, 2007). Seitzer et al. (1997) found TNF-308 A
overrepresented in sarcoidosis patients classified as Lo¨fgren’s
syndrome (16 patients) compared to non-Lo¨fgren’s sarcoido-
sis patients (85 patients) and healthy controls (216 controls)
(Seitzer et al., 1997). They also noted a trend toward an
association of an SNP in the first intron of LTA (the same SNP
in this study) in the Lo¨fgren’s syndrome patients (Seitzer et al.,
1997). The same group reported an association between
TNF-308 A and Lo¨fgren’s syndrome in a second study
involving 16 Lo¨fgren’s patients, 62 non-Lo¨fgren’s sarcoidosis
patients, and 50 controls (Swider et al., 1999). Labunski et al.
(2001) showed an association between TNF-308 A and 10
sarcoidosis patients with EN compared to 10 patients with EN
without underlying sarcoidosis and 17 control patients with
granulomas annulare or acute drug eruption. Mrazek et al.
(2005) also found TNF-308 A overrepresented in 16 Lo¨fgren’s
syndrome sarcoidosis patients compared to 98 non-Lo¨fgren’s
sarcoidosis patients and 232 controls. In addition, LTAþ252
G (the same SNP in this study and the one by Seitzer et al.,
1997) was also associated with the 16 Lo¨fgren’s syndrome
sarcoidosis patients compared to 98 non-Lo¨fgren’s sarcoido-
sis patients and 232 controls, as well as an additional control
group of 193 individuals (Mrazek et al., 2005). These studies
provided congruent evidence of a role for the LTA/TNF locus
in development of skin complications in sarcoidosis.
A prior study using a subset of the ACCESS population,
which detected an increase in a genetic marker of immu-
noglobulin k chains in African-American patients without EN
compared to non-disease matched controls, did not detect an
association of TNF-308 A in 278 Caucasian sarcoidosis
patients with EN (proportion unreported) compared with
matched non-sarcoidosis controls, or when sarcoidosis
patients without EN (proportion unreported) were compared
with matched non-sarcoidosis controls (Pandey and
Frederick, 2002). Using the entire ACCESS collection of
Caucasian patients (362 with genotype and racial data), we
demonstrated a significant association between LTA/TNF
variants and EN in Caucasian sarcoidosis patients. The different
conclusions drawn by the two ACCESS studies could be due to
the different numbers of patients studied. However, of
potentially greater importance is that the first ACCESS study
did not compare Caucasian sarcoidosis patients with and
without EN to each other as was done in this study.
It is interesting to note that no previous studies evaluated
male and female patients separately for genetic association
with TNF or LTA even though the prevalence of EN is
increased in female sarcoidosis patients. Grouping of ACCESS
Caucasian patients with EN by sex reveals that female
patients have a robust association with LTA and a near-
study-wide significant association with TNF. These two genes
are next to each other and variants in each gene that associate
with EN are almost always found together (Barrett et al.,
2005; Mrazek et al., 2005). Thus, either variant, both
variants, or an as yet unidentified variant residing nearby
appears responsible for the major skin complication of
sarcoidosis. These variants may contribute to EN by altering
the levels of TNF, LTA, or both or by some other mechanism.
There is evidence that TNF-308 A may increase TNF levels by
increasing the transcription of TNF (Kroeger et al., 1997;
Wilson et al., 1997). It is noteworthy that when Caucasian
sarcoidosis patients with ‘‘high risk’’ LTA genotypes are
removed, prevalence of EN is unchanged in male patients
(5.5%) but decreases from 10 to 6.2% in female patients,
suggesting that the higher prevalence of EN in female patients
is due to variation in the LTA/TNF locus. This sex-dependent
effect may not be limited to Caucasians, as female African-
American sarcoidosis patients in this study also displayed
evidence of association between LTA/TNF variants and EN.
TNF is a compelling biological candidate for the sex-
dependent difference in EN as it has been shown to be
upregulated by estradiol, which in turn regulates the fate of
T-cells (Cutolo et al., 2003; Hirano et al., 2006). The presence
of high levels of estradiol in female patients may enhance the
physiological effect of the genetic variation in TNF, leading to
substantial elevation of this potent cytokine. In support of this
conjecture is the observation that the prevalence of EN in male
and female patients is similar before puberty (Gordon, 1961;
Soderstrom and Krull, 1978). LTA could also be involved, as it
has 50% homology with TNF and both TNF and LTA share
receptors and act as modulators of the immune response
(Aggarwal et al., 1985; Porter, 1990; Bradley, 2008). An
association between LTA/TNF locus variation and presence of
EN increases confidence that these protein products play an
etiologic role in skin sarcoidosis. Thus, therapies directed
against these proteins may be effective, especially for female
patients (Sheskin, 1980; Alexis and Strober, 2005; Baughman
et al., 2006; Faber et al., 2006).
MATERIALS AND METHODS
Patients and controls
Sarcoidosis patients and controls were recruited by ACCESS: a
multi-center study designed to examine the etiology of sarcoidosis
1924 Journal of Investigative Dermatology (2009), Volume 129
KE McDougal et al.
Modifier of Erythema Nodosum
and the socioeconomic status and clinical course of patients with
sarcoidosis (ACCESS Research Group, 1999). Center study protocols
were approved by their local Institutional Review Board, and
Declaration of Helsinki protocols were followed. The experiments
in this work were approved by the Johns Hopkins University
Institutional Review Board. Written informed consent was received
from all participating individuals. Seven hundred six matched pairs
(1412 individuals) were recruited between November 1996 and June
1999 (Rybicki et al., 2001a). All patients had active sarcoidosis
confirmed by biopsy within 6 months prior to recruitment. The study
design and sarcoidosis assessment instruments of ACCESS have been
described in detail (ACCESS Research Group, 1999; Judson et al.,
1999). Briefly, organ involvement was assessed in each subject by a
physician participating in ACCESS using a system based on the
subject’s history, physical examination, and laboratory tests (Judson
et al., 1999). For each patient, biopsy data and laboratory results
were compared with organ involvement data to confirm the
diagnosis. Patients were matched with controls based on age, sex,
self-reported ethnicity, and geographic area. Poor quality or lack of
DNA prevented genotyping of 60 individuals in ACCESS. Thirty-five
genotyped individuals missing racial data were excluded. A total of
726 Caucasian samples (362 cases/364 controls) and 591 African-
American samples (297 cases/294 controls) were analyzed.
Selection and genotyping of candidate SNPs
Twenty-five SNPs in genes encoding proteins involved in T-cell-
mediated inflammatory responses were chosen based upon biolo-
gical relevance or previously published association with sarcoidosis
(Table S7). Genotyping was performed by hybridization of PCR-
amplified DNA fragments encompassing each SNP to allele-specific
oligonucleotides in linear arrays (Baxter et al., 2001; Wang et al.,
2002; Barcellos et al., 2004; Buranawuti et al., 2006). Multiplex PCR
with biotinylated primers was performed as previously reported
(Baxter et al., 2001; Wang et al., 2002; Barcellos et al., 2004;
Buranawuti et al., 2006). Arrays were hybridized and washed using a
BeeBlot machine (Product Number 1003, manufactured by Bee
Robotics Ltd., UK) with BeeBlot Programmable Software V2.1b.
Assay conditions were as follows: hybridization 531C for 15minutes;
wash 251C for 1minute; conjugation 541C for 5minutes; wash 251C
for 1minute; wash 541C for 12minutes; citrate 251C for 5minutes;
substrate 251C for 25minutes; deionized water 251C for 5minutes
(3 ). Genotypes were determined using image analysis software
(StripScan 5.3.5) provided by Roche Molecular Systems.
Descriptive and statistical analyses
Allele and genotype frequencies were estimated using the genassoc
package available for STATA (http://www.stata.com) and confirmed
in SAS version 8.2 (http://www.sas.com/SAS). For allele frequencies
please see Table S8. Tests of fit to Hardy–Weinberg proportions
were also performed in controls using genassoc (http://www-gene.
cimr.cam.ac.uk/clayton/software/stata/genassoc/). SNP rs1799987
(http://www.ncbi.nlm.nih.gov/SNP) in Caucasians and SNP rs333
in African Americans did not conform to HWE predictions and were
removed from further analysis in these groups.
Logistic regression was used to estimate genotype odds ratios for
each SNP, and Wald tests were performed to assess statistical
significance by computing study-wide P-values in SAS version 8.2.
Permutation testing, through random shuffling of case–control status,
was performed for the 24 SNPs conforming to HWE predictions in
African Americans or Caucasians. We obtained an empirical P-value
estimated by the proportion of permuted data sets with a Wald test
for an SNP greater than the observed test value for that SNP. To
correct for false positives due to multiple testing, we extended the
permutation procedure to obtain a study-wide threshold for a given
type 1 error rate that accounts for all SNP tests performed. This was
constructed using distribution of maximum Wald values (maxT)
across 24 tests of single SNPs at each permutation. The maxT
distribution accounts for 24 tests while allowing for correlations
between SNPs when computing a multiple-test adjusted empirical
P-value for each SNP (Westfall et al., 2002). We calculated study-
wide empirical P-values for each SNP as proportions of maximum
Wald test values among permuted data sets greater than the
observed value for each SNP. One thousand permutations were
performed and we considered SNPs with a study-wide Pp0.05
statistically significant associations. Analyses using 10,000 permuta-
tions did not produce P-values that were different from those with
1,000 permutations. Testing and permutation methods did not
directly incorporate the matched design of ACCESS. We adjusted for
matching factors using unconditional logistic regression that
adjusted for each factor while estimating genotype odds ratios,
rather than using a conditional logistic regression model without
these covariates. This approach causes minimal bias of odds ratio
estimates when adjusting by matching factors, as long as they are not
very strong confounders (Breslow et al., 1978). Given different allele
frequencies and potential for different risk effect sizes between races,
we analyzed Caucasian and African-American samples separately.
Haplotype analysis was performed using the Exhaustive Allelic
Case–Control method as described earlier (Lin et al., 2004).
FDR was also estimated by computing a Q-value from an
uncorrected P-value for each test, using the distribution of observed
test statistics (Storey and Tibshirani, 2003). A Q-value represents the
proportion of false positives controlled for by accepting significance at
a particular observed P-value. In this study, we considered Q-values
of 0.05 or less as an acceptable proportion of false positives in
combination with a study-wide P0.05. Q-values were estimated from
single-test empirical P-values by the bootstrap estimation method
using the Q-value package in R (http://cran.r-project.org/) (Benjamini
and Hochberg, 1995; Storey and Tibshirani, 2003).
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